While BCAA restriction synergized with bevacizumab to reduce HCT116 tumor growth via nutrient limitation (Fig. 7C), preliminary data with FOLFOX showed similar tumor suppression (Supplementary Fig. 5C). This evidence concerns the gene ARID4B and neoplasm.